Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Taurochenodeoxycholic Acid [516-35-8]
Cat# T2A2481-500mg
Size : 500mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
Taurochenodeoxycholic Acid
Catalog No. T2A2481 CAS 516-35-8
Synonyms: Chenodeoxycholyltaurine, TCDCA, Chenyltaurine, Taurochenodeoxycholate, 12-Deoxycholyltaurine
Taurochenodeoxycholic Acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid.
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Taurochenodeoxycholic Acid, CAS 516-35-8
| Description | Taurochenodeoxycholic Acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. |
| In vitro | Studies have suggested that taurochenodeoxycholic acid as a signaling molecule shows obvious anti-inflammatory and immune regulation properties. Taurochenodeoxycholic acid dramatically improves the apoptosis rate of NR8383 cells in a concentration-dependent manner. In the meantime, PKC mRNA levels and activities are significantly augmented by taurochenodeoxycholic acid treatments. In addition, JNK, caspase-3 and caspase-8 mRNA expression levels and activities are increased by taurochenodeoxycholic acid. |
| In vivo | Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation. Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats.Taurochenodeoxycholic acid in dosages of 0.05 and 0.1g/kg can decrease the pulmonary coefficient in the model mice, taurochenodeoxycholic acid in dosages of 0.05 and 0.1g/kg reduce the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice, the expression level of MMP-9 increases, while it has no significant effects on MMP2. |
| Synonyms | Chenodeoxycholyltaurine, TCDCA, Chenyltaurine, Taurochenodeoxycholate, 12-Deoxycholyltaurine |
| Molecular Weight | 499.7 |
| Formula | C26H45NO6S |
| CAS No. | 516-35-8 |
Storage
Solubility Information
DMSO: > 22 mg/mL (44.03 mM)
References and Literature
1. Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15. 2. Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5. 3. Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57. 4. Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8.